# ADNI_amyloid_generalizability

This is the code for Workgroup 3 "Generalizing findings from biomarker and neuropathology studies to populations" from the PsyMCA 2021 Conference.

## Working title

**Generalizing the [presumed] causal effect of change in PET amyloid and change in cognition observed in ADNI to US older adults meeting appropriate use criteria for Aduhelm (aducanumab)**

## Description

Estimating the [causal] association of amyloid and cognition, and change in the same over 6 years, in ADNI and transporting (based on demographics and selected potential confounders) to a sub-sample from the HRS meeting Cummings et al (2021) appropriate use criteria for Aduhelm.

## Resources

The planning document in a [google document](https://docs.google.com/document/d/11KIGtJgfc7a8XOWL-yiW5OcoYPAidm5INFuw5ZaksBw/edit?usp=sharing).

The ENGAGE/EMERGE eligibility criteria in [google sheet](https://docs.google.com/spreadsheets/d/1w9lj9bmG6bg8Ze5i5NM5NhJRbLz_S0e0KQthKTF1ysw/edit?usp=sharing).
